Ursofalk

Ursofalk (Ursodeoxycholic acid) is the gold standard therapy for cholestatic liver diseases and cholesterol gallstones. Back in 1981, a group of gastroenterologists from Frankfurt (Germany), led by Prof. U. Leischner. Leischner, successfully used Ursofalk to dissolve gallstones in patients with chronic hepatitis1.

Ursodeoxycholic acid is a hydrophilic, non-cytotoxic bile acid, the content of which in human bile is about 1%. It is the least aggressive bile acid – a natural component of human bile1.

The main properties of ursodeoxycholic acid are:

– litholytic
– immunomodulatory
– apoptotic
– hepatoprotective
– antifibrotic
– inhibition of cholesterol absorption in the intestine.

Ursofalk is an original German preparation of ursodeoxycholic acid, which is registered in 74 countries of the world and has been successfully used in practice for more than 35 years. It is used as a reference drug in registration of ursodeoxycholic acid preparations.

The use of Ursofalk in patients with primary biliary cirrhosis can increase survival rate, slow disease progression and prevent complications 2-4.

Ursofalk also dissolves cholesterol gallstones and reduces the concentration of cholesterol in bile, allows to reduce or eliminate dyspeptic symptoms5,6.

A wide range of release forms allows you to choose the necessary dosage depending on the clinical situation.

Ursofalk is an original ursodeoxycholic acid with proven efficacy in the treatment of liver and biliary tract diseases.

1. Ursofalk® in clinical practice – Freiburg: Dr. Falk Pharma GmbH, 2010.
2. Leuschner U. et al.  Effects of ursodeoxycholic acid after 4 to 12 years of therapy in early and late stages of primary biliary cirrhosis. J Hepatol. 1994; 21(4):624-33.
3. Lindor K.D. et al. Effects of Ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. Gastroenterology 1996; 110:1515–1518.
4. Lindor K.D. et al. Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis. Mayo Clin Proc. 1997; 72(12):1137-40.
5. Stiehl E.T. et al. Effects of biliary bile acid composition on biliary cholesterol saturation in gallstone patients treated with chenodeoxycholic acid and/or ursodeoxycholic acid. Gastroenterology 79:1192-119189, 1980.
6. Ventura P. et al. A double-blind controlled trial of the efficacy and safety of taurohyodeoxycholic acid in the treatment of dyspeptic disturbances associated with gallstones or other hepatic disorders. Clinical Drug Investigation, 1996;11(2), 77–83.